Drs. Michael Davies, Philip Barter, and Jonathan Golledge join Medical Advisory Board.

Drs. Michael Davies, Philip Barter, and Jonathan Golledge join Medical Advisory Board.

After months of vetting, Reven, selected INC Research clinical research organization (CRO) partner. They will be assisting with administration, project management, and execution of the various processes involved in patient care delivery throughout the trial.

Reven hired Kristina Cabala as Reven’s Global Head of Clinical Affairs.

Patent approved in Australia.

Our South African Chief Scientist and Senior Quality Control Manager (and inventors of Rejuveinix) Henk and Mariette van Wyk formally received their permanent residence Green Cards.

The Reven team is proud to announce their latest US patent allowance, titled “Methods of Treating or Ameliorating Diseases and Enhancing Performance Comprising the use of a Magnetic Dipole Stabilized Solution”. This patent gives us the future opportunity to expand … Read More

Investigational New Drug (IND) submitted to FDA. Formal evaluation and FDA collaboration continue to create human clinical trial protocols.

Furthered discussions with esteemed medical centers to begin multi-center Phase I/II trials.

Reven begins Investigational New Drug (IND) process with FDA.

Our chief scientist is from South Africa and he was recently approved for a National Interest Waiver visa from the US Citizenship and Immigration Services (USCIS). This process took two years and ultimately, USCIS decided that having our Chief Scientist … Read More

Reven hires Allie Lopez as Clinical Director.

2015 Year-End Shareholder Update posted to the Investor Portal.

Reven, in conjunction with its research partner, validated six bio analytical assays for its vascular drug, RJX.

The Australian Patent Office allows Reven its first Australian patent.